Citations

Showing 10 of 108162 citations.

Not a Tumor-Nonspecific Orbital Inflammation
Garrity, James A.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 3, 2021 | Volume: 82 | Issue: 01 | Pages: 096-099

10.1055/s-0040-1722636 | PMID 33777622 Get It

Abstract Objective This study was aimed to illustrate the features and complexities of nonspecific orbital inflammation via discussion of two representative cases. Design Present study is a retrospective case review. Setting The study was conducted at a tertiary care medical center. Participants Two patients with nonspecific orbital inflammation were participants of this retrospective study. Main Outcome Measures Outcome of the study was disease-free patients and off all medications. Results At follow-up, both patients are disease free and off all medications. Conclusion Surgery plays a diagnostic and therapeutic role. While the clinical subtype is important for differential diagnosis and symptomatic treatment, the histologic subtype is similarly important. For inflammatory dacryoadenitis, surgery can be therapeutic. For extensive granulomatosis with polyangiitis, debulking surgery may allow better penetration of medications, especially rituximab.
Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
Khurana, Arushi , Mwangi, Raphael , Nowakowski, Grzegorz S. , Ansell, Stephen M. , LaPlant, Betsy, Link, Brian K. , Cerhan, James R. , Maurer, Matthew J. , Witzig, Thomas E. , Ansell, Stephen M , LaPlant, Betsy R, Link, Brian K , Cerhan, James R , Maurer, Matthew , Witzig, T.E. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | February 2, 2021 | Volume: 39 | Issue: 15 | Pages: 1641-1649

10.1200/jco.20.01935 | PMID 33529046 Get It

PURPOSE Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of diffuse large B-cell lymphoma (DLBCL). The impact of baseline organ function–based eligibility criteria on this effect and clinical trial exclusion is less well-understood. METHODS Consecutive patients with newly diagnosed lymphoma were enrolled from 2002 to 2015 into the Molecular Epidemiology Resource (MER) of the University of Iowa and Mayo Clinic Lymphoma Specialized Program of Research Excellence. The current analysis includes 1,265 patients with DLBCL receiving standard immunochemotherapy. Organ function parameters were identified from criteria for hemoglobin, absolute neutrophil count, platelet count, creatinine clearance, and bilirubin, as reported in frontline DLBCL trials. Abstracted laboratory values from MER were used to determine the percent (%) of patients excluded. Outcomes and cause-of-death analyses comparing ineligible and eligible groups in MER were conducted. An interactive online tool was developed to estimate exclusions based on organ function for future trial design. RESULTS Between 9% and 24% of MER patients with DLBCL receiving standard immunochemotherapy were excluded on the basis of baseline organ function alone. Ineligible patients based on organ function had significantly inferior event-free survival (hazard ratios, 1.67-2.16), overall survival (hazard ratios, 1.87-2.56), and event-free survival at 24 months (odds ratio, 1.71-2.16). Ineligible patients were more likely to die from lymphoma progression than increased therapy-related complications. CONCLUSION Current national and international trials exclude up to 24% of patients from participation on the basis of organ function alone. A significant difference in the outcomes, notably lymphoma-related death, suggests issues with generalization and potential exclusion of high-risk patients. These data will help future clinical trial development and meet US Food and Drug Administration and ASCO recommendations to increase trial accrual.
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
García‐Pavía, Pablo , Adler, Yehuda , Arad, Michael , Basso, Cristina , Brucato, Antonio , Burazor, Ivana , Damy, Thibaud , Eriksson, Urs , Fontana, Marianna , González-López, Esther , Grogan, Martha , Heymans, Stéphane , Kindermann, Ingrid , Kristen, Arnt V. , Merlini, Giampaolo , Pantazis, Antonis, Pankuweit, Sabine , Rigopoulos, Angelos G. , Basso, Cristina , Brucato, Antonio , Merlini, Giampaolo , Gillmore, Julian D , Garcia-Pavia, Pablo , Heymans, Stephane , Basso, Cristina , Rapezzi, Claudio , Basso, Cristina , Caforio, Alida L.P. , Fontana, Marianna , Gillmore, Julian D. , Imazio, Massimo , Maurer, Matthew J. , Linhart, Aleš

Mayo Clinic

European Heart Journal | February 2, 2021 | Volume: 42 | Issue: 16 | Pages: 1554-1568

10.1093/eurheartj/ehab072 | PMID 33825853 Get It

Abstract Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.
Peripheral Markers of Neurovascular Unit Integrity and Amyloid-β in the Brains of Menopausal Women
Jayachandran, Muthuvel , Miller, Virginia M. , Lahr, Brian D. , Bailey, Kent R. , Lowe, Val J. , Fields, Julie A. , Kantarci, Kejal , Kantarci, Kejal , Mielke, Michelle M.

Mayo Clinic

Journal of Alzheimer's Disease | February 2, 2021 | Volume: 80 | Issue: 1 | Pages: 397-405

10.3233/jad-201410 | PMID 33554914 Get It

Background: The identification of blood-borne biomarkers for the diagnosis and prognosis of Alzheimer’s disease and related dementias is more feasible at the population level than obtaining cerebrospinal fluid or neuroimaging markers. Objective: This study determined the association of blood microvesicles, derived from cells of the neurovascular unit, with brain amyloid-β deposition in menopausal women. Methods: A subset of women from the Kronos Early Estrogen Prevention Study underwent brain amyloid-β positron emission tomography three years following cessation of study treatment with placebo (PL, n = 29), transdermal 17β-estradiol (tE2; n = 21), or oral conjugated equine estrogen (oCEE; n = 17). Isolated peripheral venous blood microvesicles were analyzed by digital flow cytometry using fluorophore conjugated antibodies directed toward total tau, amyloid-β 1–42 (Aβ1–42), neuron specific class III β-tubulin (Tuj1), microglia ionized calcium -binding adaptor molecule 1(Iba1), glial fibrillary acid protein (GFAP), and low density lipoprotein receptor-related protein1 (LRP1). Principal components analysis reduced the dimensionality of these selected six markers to two principal components (PCs). Proportional odds ordinal logistic regression analysis was used with amyloid-β deposition regressed on these PCs. Results: Only the number of microvesicles positive for Aβ1–42 differed statistically among prior treatment groups (median [IQR]: 6.06 [2.11, 12.55] in PL; 2.49 [0.73, 3.59] in tE2; and 4.96 [0.83, 10.31] in oCEE; p = 0.032). The joint association between the 2 PCs and brain amyloid-β deposition was significant (p = 0.045). Conclusion: Six selected markers expressing peripheral blood microvesicles derived from cells of the neurovascular unit, when summarized into two principal components, were associated with brain amyloid-β deposition.
The Genetics of Sudden Infant Death Syndrome—Towards a Gene Reference Resource
Johannsen, Emma B. , Sharma, Neeraj , Zjacic, Nicolina , Pirooznia, Mehdi , Elhaik, Eran , Zjacic, Nicolina , Pirooznia, Mehdi , Elhaik, Eran , Baughn, Linda B. , Sharma, Neeraj

Mayo Clinic

Genes | February 2, 2021 | Volume: 12 | Issue: 2 | Pages: 216

10.3390/genes12020216 | PMID 33540853 Get It

Sudden infant death syndrome (SIDS) is the unexpected death of an infant under one year of age that remains unexplained after a thorough investigation. Despite SIDS remaining a diagnosis of exclusion with an unexplained etiology, it is widely accepted that SIDS can be caused by environmental and/or biological factors, with multiple underlying candidate genes. However, the lack of biomarkers raises questions as to why genetic studies on SIDS to date are unable to provide a clearer understanding of the disease etiology. We sought to improve the identification of SIDS-associated genes by reviewing the SIDS genetic literature and objectively categorizing and scoring the reported genes based on the strength of evidence (from C1 (high) to C5 (low)). This was followed by analyses of function, associations between genes, the enrichment of gene ontology (GO) terms, and pathways and gender difference in tissue gene expression. We constructed a curated database for SIDS gene candidates consisting of 109 genes, 14 of which received a category 4 (C4) and 95 genes received the lowest category of C5. That none of the genes was classified into the higher categories indicates the low level of supporting evidence. We found that genes of both scoring categories show distinct networks and are highly diverse in function and involved in many GO terms and pathways, in agreement with the perception of SIDS as a heterogeneous syndrome. Genes of both scoring categories are part of the cardiac system, muscle, and ion channels, whereas immune-related functions showed enrichment for C4 genes. A limited association was found with neural development. Overall, inconsistent reports and missing metadata contribute to the ambiguity of genetic studies. Considering those parameters could help improve the identification of at-risk SIDS genes. However, the field is still far from offering a full-pledged genetic test to identify at-risk infants and is still hampered with methodological challenges and misunderstandings of the vulnerabilities of vital biological mechanisms.
Predominance of Atopobium vaginae at Midtrimester: a Potential Indicator of Preterm Birth Risk in a Nigerian Cohort
Odogwu, Nkechi Martina , Onebunne, Chinedum Amara , Jeraldo, Patricio , Yang, Lu , Johnson, Stephen , Ayeni, Funmilola A. , Walther-António, Marina , Olayemi, Oladapo O., Omigbodun, Akinyinka , Walther-Antonio, Marina R S, Chia, Nicholas , Jeraldo, Patricio R , Walther-Antonio, Marina , Chen, Jun , Olayemi, Oladapo O.

Mayo Clinic

mSphere | February 2, 2021 | Volume: 6 | Issue: 1 | Pages: No page available

10.1128/msphere.01261-20 | PMID 33504666 Get It

Giving birth too soon accounts for half of all newborn deaths worldwide. Clinical symptoms alone are not sufficient to identify women at risk of giving birth too early, as such a pragmatic approach to reducing the incidence of preterm birth entails developing early strategies for intervention before it materializes.
Physicians’ Electrocardiogram Interpretations—Reply
Cook, David A. , Pusic, Martin , Pusic, Martin V

Mayo Clinic

JAMA Internal Medicine | February 2, 2021 | Volume: 181 | Issue: 5 | Pages: 722

10.1001/jamainternmed.2020.8652 | PMID 33523118 Get It

Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
Houten, Holly K. Van , Deng, Yihong , Mandic, Pinar Karaca, Shah, Nilay D. , McCoy, Rozalina G. , Deng, Yihong , Karaca‐Mandic, Pinar , Ross, Joseph S. , Montori, Víctor M.

Mayo Clinic

JAMA Network Open | February 2, 2021 | Volume: 4 | Issue: 2 | Pages: e2035792

10.1001/jamanetworkopen.2020.35792 | PMID 33523188 Get It

Association of Premenopausal Bilateral Oophorectomy With Restless Legs Syndrome
Huo, Nan , Rocca, Liliana Gazzuola , Rocca, Walter A. , Gazzuola Rocca, Liliana, Smith, Carin Y. , Mielke, Michelle M. , Huo, Nan

Mayo Clinic

JAMA Network Open | February 2, 2021 | Volume: 4 | Issue: 2 | Pages: e2036058

10.1001/jamanetworkopen.2020.36058 | PMID 33523190 Get It